Intensity Therapeutics (INTS) Presents Positive INT230-6 Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023
November 2, 2023 7:01 AM EDTThe disease control rate for subjects in the monotherapy was 93% for patients who received at least one dose of INT230-6
INT230-6 extended survival in refractory soft tissue sarcoma subjects by nearly 15 months when compared to a synthetic control group
In the study, INT230-6 was found to have a favorable safety profile and be well tolerated, with approximately 90% adverse events being grade 1 or 2
WESTPORT, Conn., Nov. 2,... More
